Ugur Sahin (L) and Özlem Türeci (Bernd von Jutrczenka/picture-alliance/dpa/AP Images)
November 22, 2021 06:45 AM ESTUpdated 08:15 AM
FDA+
Coronavirus

New Pfiz­er/BioN­Tech Covid vac­cine da­ta in teens show strong pro­tec­tion, lin­ing up sBLA fil­ing

Zachary Brennan

Senior Editor

Pfiz­er and BioN­Tech are plan­ning to file for full ap­proval of their Covid-19 vac­cine for all of those over the age of 12 af­ter they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bio­gen gets $250M in Roy­al­ty Phar­ma deal for Phase 3 lu­pus pro­gram

Af­ter pass­ing on M&A of­fers, Abcuro rais­es $200M in bid to be­come com­mer­cial drug­mak­er

Spring­Works lands FDA ap­proval for nerve tu­mor treat­ment

Ex­clu­sive: Longevi­ty start­up tar­gets rene­gade pro­teins linked to di­a­betes and obe­si­ty

What will phar­ma's share buy­back shop­ping spree mean for M&A?

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times